EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma

Eva-Maria Klein, Sejla Hujic, Kaya Miah, Axel Benner, Maximilian Merz, Uta Bertsch, Niels Weinhold, Hartmut Goldschmidt, Sandra Sauer

Oncology · 2024

DOI: 10.1159/000541541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Eva-Maria Klein und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Neoplasm Recurrence, Local. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although recent data suggest that melphalan high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT) is safe and effective in eligible multiple myeloma (MM) patients up to the age of 75 years, its value in elderly MM patients is still controversially discussed.

Methods

We retrospectively analyzed 607 MM patients ≥60 years old, who were admitted to our institution for first-line or salvage HDT/ASCT between January 2007 and October 2018. We assigned them to three groups according to age at HDT/ASCT: 60–64 years (S1), 65–69 years (S2) and ≥70 years (S3). We compared progression-free and overall survival, duration of hospitalization, complications, transfers to intermediate or intensive care unit, readmissions after discharge and deaths within 100 days after HDT/ASCT between these groups.

Results

Age did not impact progression-free and overall survival after first-line and salvage HDT/ASCT. Patients ≥70 years old at first HDT/ASCT had a longer hospitalization compared to patients 60–64 years old; however, the difference in the length of hospitalization was only marginal. Rates of febrile neutropenia, mucositis, transfers to intermediate or intensive care unit, readmissions after discharge, and deaths within 100 days after HDT/ASCT were similar in the 3 age groups of patients receiving first or salvage HDT/ASCT. Patients with a Charlson Comorbidity Index ≥2 receiving first HDT/ASCT had a higher risk for a transfer to intermediate or intensive care unit.

Conclusion

Our analysis shows that HDT/ASCT is safe and effective in eligible elderly MM patients in first-line treatment and at relapse. A careful patient selection according to biological rather than chronological age is of crucial importance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationNeoplasm Recurrence, LocalHumansAgedFemaleMiddle AgedMaleRetrospective StudiesTransplantation, AutologousAge FactorsSalvage TherapyMelphalanTreatment Outcome

Stichwörter der Autor:innen

Autologous stem cell transplantationElderly patientsMultiple myelomaSurvivalToxicity

Substanzen

Melphalan

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
  • Department of Internal Medicine 5, Klinikum Nuremberg, Paracelsus Medical University, Nuremberg, Germany.
  • Department of Internal Medicine/Cardiology, GRN Klinikum Schwetzingen, Schwetzingen, Germany.
  • Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Hematology, Cell therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany.
  • National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Zitieren

APA

Klein, E. M., Hujic, S., Miah, K., Benner, A., Merz, M., Bertsch, U., Weinhold, N., Goldschmidt, H., & Sauer, S. (2024). Efficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma. Oncology. https://doi.org/10.1159/000541541

Vancouver

Klein EM, Hujic S, Miah K, Benner A, Merz M, Bertsch U, et al. Efficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma. Oncology. 2024. doi:10.1159/000541541

BibTeX
@article{Klein2024,
  author = {Klein, Eva-Maria and Hujic, Sejla and Miah, Kaya and Benner, Axel and Merz, Maximilian and Bertsch, Uta and Weinhold, Niels and Goldschmidt, Hartmut and Sauer, Sandra},
  title = {Efficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000541541}
}
Kostenlos starten →